ACTRN12617000994381
Recruiting
Phase 1
Evaluating ease of use and acceptability of a perineal measuring device (Episiometer) in ensuring correct angle and length of mediolateral episiotomy: a mixed methods study
Professor Ajay Rane0 sites120 target enrollmentJuly 10, 2017
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Episiotomy
- Sponsor
- Professor Ajay Rane
- Enrollment
- 120
- Status
- Recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
N/A
Evaluating the acceptability and usability of a digital self-management intervention (smartphone application) to support the non-surgical treatment of Perthes' DiseasePerthes' DiseaseMusculoskeletal DiseasesISRCTN14517832niversity of Leeds30
Active, Not Recruiting
N/A
Precision Atrial Fibrillation App to support Atrial Fibrillation ManagementAtrial FibrillationCardiovascular - Other cardiovascular diseasesACTRN12623001051639The University of Adelaide30
Recruiting
N/A
Pilot trial of the Health4Life apppoor dietinsufficient physical activityalcohol usetobacco usepoor sleepexcessive recreational screen timePublic Health - Health promotion/educationACTRN12622001087741HMRC CTC75
Completed
N/A
The usability and preliminary effectiveness of an app-based training and educational program (Join2Move) in people with hip and/ or knee osteoarthritis – a randomized controlled pilot studyPolyarthrosisPeople with hip and/ or knee OA diagnosed by a physician or self-reported OA. Self-reported OA should meet the criteria of idiopathic OA of the hip (Altman et al., 1991) or OA of the knee (Altman et al., 1986).M15M16M17Coxarthrosis [arthrosis of hip]Gonarthrosis [arthrosis of knee]DRKS00027164Hochschule für Gesundheit Bochum61
Active, Not Recruiting
Phase 1
To assess ease of use, acceptability and preference of Norditropin NordiFlex® in subjects on prescribed growth hormone therapychildren aged 6 years or more receiving growth hormone therapy for the following approved indications (according to Norditropine SPC)-GHD-Turner Syndrome-small for gestational age-chronic renal insufficiencyEUCTR2009-017387-16-FRovo Nordisk Pharmaceutique S.A.S